Gyros Protein Technologies and Cygnus Technologies are joining forces to improve bioprocess impurity analytics and introduce the ready-to-use solutions for Gyrolab with reagent sets from Cygnus that are developed for use with the Gyrolab technology.
The HEK 293 HCP and EndonucleasGTP Solutions for Gyrolab offer the following benefits:
HEK 293 cell lines are commonly used in the production of viral vectors for cell and gene therapy applications and vaccines. Residual host cell proteins (HCP) have the potential to affect product quality, safety, and efficacy and must therefore be reduced to a minimum and monitored closely during downstream bioprocessing and in the final drug product.
The ready-to-use HEK293 HCP Solution for Gyrolab consists of the HEK 293 HCP Assay Reagent Set for Gyrolab from Cygnus, designed and validated for use with Gyrolab Bioaffy 1000 HC Assay Toolbox. It quickly delivers high quality HCP quantification from sample volumes of less than 10 μL from different stages of a bioprocess run.
During manufacturing of recombinant viral vectors or vaccines, cells are transfected with plasmid DNA. As part of lysis, endonuclease is added to digest DNA and RNA. The amount of residual endonuclease needs to be assessed during downstream purification process and the final amount of endonuclease present in the final product also needs to be quantitated as critical quality attribute.
To meet this need, the EndonucleaseGTP Solution for Gyrolab has been developed for sensitive detection of residual endonuclease impurities. The solution consists of EndonucleaseGTP® Assay Reagent Set for Gyrolab from Cygnus Technologies and Gyrolab Bioaffy 1000 HC Assay Toolbox.
It is suitable for the detection of genetically engineered endonucleases such as Benzonase® Nuclease and Denarase®
High-throughput, automated analysis of viral vector titer and process related impurities accelerates downstream process development of AAV based gene therapies
Learn how to perform up to 5 titer and impurities analysis in one single run
Go beyond expectations in viral vector analytics, cell and gene therapy process development and quality control
In this webinar you will hear from three independent speakers how the automated, Gyrolab immunoassay platform can help break barriers in AAV viral vector analytics, by increasing throughput and productivity, improve analytical capability and data quality, shorten data-driven decisions in process optimization and support transfer to a GMP regulated environment.